Condylomata Acuminata clinical trials
The registry lists 116 studies for Condylomata Acuminata across more than 10 countries. 11 are recruiting or about to start. 73 of them are mainly about Condylomata Acuminata (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.
Get an email when these change. Save the Condylomata Acuminata studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Merck Sharp & Dohme LLC (19) · Shanghai Bovax Biotechnology Co., Ltd. (12) · Xiamen University (7) · MediGene (3) · Beijing Health Guard Biotechnology, Inc (3) · Jun Zhang (3) · Duke University (2) · Assiut University (2)
What is being tested here
Drugs under test in Condylomata Acuminata studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5, phase 3 first
- Jul 2027A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males · Phase 3 · Shanghai Bovax Biotechnology Co., Ltd.
- Sep 2027Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females · Phase 3 · Shanghai Bovax Biotechnology Co., Ltd.
- May 2027Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine · Shanghai Bovax Biotechnology Co., Ltd.
- Aug 2027Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel · KTH Biopharma
- Oct 2027Efficacy and Safety of Oral Ivermectin for Genital Warts · University of Health Sciences Lahore
Who these studies take
Of the 6 Condylomata Acuminata studies recruiting now, 1 (17%) set no upper age limit and 5 (83%) stop at 75 or younger. 4 (67%) take children under 18. 4 (67%) are for women only and 0 (0%) for men only; 5 (83%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (67%) | 1 (17%) |
| 18 | 5 (83%) | 2 (33%) |
| 30 | 5 (83%) | 2 (33%) |
| 40 | 5 (83%) | 2 (33%) |
| 50 | 1 (17%) | 1 (17%) |
| 65 | 1 (17%) | 1 (17%) |
| 75 | 1 (17%) | 1 (17%) |
| 85 | 1 (17%) | 1 (17%) |
Across all 116 studies, recruiting or not: 73% stop at 75 or younger and 71% at 65; 45% take children; 43% are for women only and 7% for men only; 57% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Condylomata Acuminata studies take
Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 24 mo15–61 · 28 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Efficacy and Safety of Oral Ivermectin for Genital WartsNov 3, 2026NCT07913321
Studies
Recruiting first, then most recently updated. Showing 50 of 116. Browse all 116 → or search them.
- Efficacy and Safety of Oral Ivermectin for Genital WartsNot yet recruitingNCT07913321Not applicable1 country
- Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa GelRecruitingNCT07698886Phase 21 country
- To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 YearsRecruitingNCT06756269Phase 21 country
- Comparison Between Efficacy of Topical 25%Podophyllin and Cryotherapy on Genital WartsNot yet recruitingNCT06809777Phase 21 country
- Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus ExposureNot yet recruitingNCT06681636Phase 22 countries
- Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV PatientNot yet recruitingNCT06587542Phase 2/3
- Peginterferon α-2b Combined CO2 Laser in Condylomata AcuminataNot yet recruitingNCT06430190Not applicable1 country
- Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesRecruitingNCT04422366Phase 31 country
- Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsRecruitingNCT04895020Phase 31 country
- Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 YearsRecruitingNCT05027776Phase 31 country
- Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV VaccineRecruitingNCT053713531 country
- Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of CondylomaCompletedNCT02520986Not applicable1 country
- Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)CompletedNCT04635423Phase 31 country
- Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital WartsCompletedNCT02750202Phase 31 country
- Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)Active, not recruitingNCT04537156Phase 31 country
- Intralesional HPV Vaccine for CondylomataCompletedNCT05087849Phase 1/21 country
- Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)CompletedNCT00092534Phase 3
- A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesActive, not recruitingNCT06866574Phase 31 country
- Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young WomenActive, not recruitingNCT061978021 country
- An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years OldActive, not recruitingNCT05056402Phase 31 country
- Long Term Follow-up of HPV Vaccine in HIV (CTN 236)CompletedNCT069157791 country
- Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital WartsCompletedNCT02377999Phase 21 country
- Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in WartsCompletedNCT051000431 country
- A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 YearsActive, not recruitingNCT06454175Phase 11 country
- A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesActive, not recruitingNCT06465914Phase 31 country
- A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsCompletedNCT03981822Phase 21 country
- Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological AssessmentCompletedNCT067009411 country
- Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
- Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health StudyCompletedNCT062971871 country
- Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-oldCompletedNCT05518201Phase 11 country
- The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions TissueCompletedNCT06281353Phase 2/31 country
- Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCompletedNCT05372016Phase 31 country
- A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy FemalesTerminatedNCT05584332Phase 31 country
- Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of AgeCompletedNCT04782895Phase 31 country
- Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineActive, not recruitingNCT02710851Phase 2
- A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant VaccineCompletedNCT03900572Phase 11 country
- Topical NVN1000 for the Treatment of External Genital and Perianal WartsCompletedNCT02462187Phase 21 country
- Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital WartsStatus unknownNCT05761002Not applicable1 country
- Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the HandsCompletedNCT00973856Not applicable1 country
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineCompletedNCT05694728Phase 21 country
- Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)Active, not recruitingNCT05314023Phase 31 country
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV VaccineCompletedNCT05680454Phase 11 country
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in ChinaActive, not recruitingNCT05662020Phase 31 country
- Topical Ethanol Extract (Piper Crocatum) for Anogenital WartsStatus unknownNCT05622916Not applicable1 country
- Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9Status unknownNCT05580341Phase 31 country
- Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent VaccineCompletedNCT02405520Phase 1
- Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCompletedNCT04425291Phase 31 country
- Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital WartsCompletedNCT00189293Phase 41 country
- Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital WartsCompletedNCT05156541Phase 31 country
- Education, Immigration and HPV Vaccination: an Informational Randomized TrialStatus unknownNCT04905030Not applicable1 country